Fibrinogen

Understand

Overview

Fibrinogen (clotting factor I) is a glycoprotein produced in the liver and circulating in blood at a relatively high concentration, serving as the direct substrate for the final step of the coagulation cascade — under the action of thrombin it's converted into insoluble fibrin, which forms the structural scaffold of a blood clot. The test measures fibrinogen concentration in blood plasma, most often using the Clauss method, and serves a dual diagnostic role: it assesses the blood's ability to clot properly and, independently of that, serves as a marker of inflammatory status and cardiovascular risk.

Fibrinogen's clinical significance stems from its dual biological nature. On one hand, it's an essential component of normal hemostasis — both its deficiency (congenital afibrinogenemia or hypofibrinogenemia, acquired consumptive coagulopathy in DIC or massive hemorrhage) and structural abnormalities (dysfibrinogenemia) can lead to a bleeding disorder. On the other hand, fibrinogen is one of the main acute-phase inflammatory proteins, whose hepatic production rises sharply under the influence of pro-inflammatory cytokines, especially interleukin 6 — for decades, this has led epidemiological studies to link its chronically elevated concentration with a higher risk of atherosclerosis, heart attack, and stroke, independent of classic lipid risk factors.

The test is ordered in several distinct clinical contexts. In diagnosing clotting disorders, fibrinogen is measured as part of a broader coagulation panel for unexplained bleeding, before surgical procedures in patients with suspected bleeding disorders, and above all in monitoring severe emergency conditions — massive obstetric hemorrhage, multi-organ trauma, or disseminated intravascular coagulation (DIC) — where a sharp drop in fibrinogen is one of the key warning signs requiring urgent correction. Independent of this, fibrinogen is sometimes included in an extended cardiovascular risk panel, especially in patients with numerous risk factors where the classic lipid profile doesn't fully explain the observed clinical risk.

Interpreting the result requires knowing the context in which the test was ordered, since the same numbers mean something different in an acute clinical situation than in routine preventive assessment. In acute hemorrhagic states and suspected DIC, what matters is a sharp drop in fibrinogen below a critical value, signaling consumption of clotting factors faster than the liver can replace them. In assessing chronic cardiovascular risk, what matters is a moderate but persistent elevation in concentration, interpreted together with other inflammatory and lipid markers, rather than a single number taken out of context.

Causes of an abnormal result are numerous and differ by direction. Elevated fibrinogen accompanies nearly every inflammatory and infectious state (as an acute-phase reaction), obesity, type 2 diabetes, smoking, pregnancy (physiologically, especially in the third trimester), and chronic inflammatory diseases. Low fibrinogen occurs in severe liver disease (its site of synthesis), in DIC and massive hemorrhage due to consumption, in congenital disorders of fibrinogen synthesis, and transiently after massive fluid transfusions without adequate replacement of clotting factors.

On the practical side, the test doesn't require strict fasting, but it's important to avoid significant physical exertion and to inform the lab of any pregnancy or anticoagulant medications, since these can affect the result or its interpretation. The sample requires proper pre-analytical preparation (a citrate tube, strict adherence to the blood-to-anticoagulant ratio), and collection errors are one of the more common causes of results that don't match the patient's actual clinical state.

Fibrinogen remains a test with dual significance — as a core parameter of hemostatic function in acute states and as an inflammatory marker with an established, though still debated as to causality, role in cardiovascular risk assessment. In clinical practice it's rarely interpreted in isolation — in the acute context it's weighed alongside the full coagulation picture (INR, APTT, platelets), and in the chronic context alongside the lipid profile and other inflammatory markers, since only that comprehensive picture allows a genuine disorder to be distinguished from a transient acute-phase reaction.